Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)

Keros Therapeutics' Retained Earnings history spans 7 years, with the latest figure at -$481.8 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 15.3% year-over-year to -$481.8 million; the TTM value through Dec 2025 reached -$481.8 million, up 15.3%, while the annual FY2025 figure was -$481.8 million, 15.3% up from the prior year.
  • Retained Earnings reached -$481.8 million in Q4 2025 per KROS's latest filing, down from -$458.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$80.9 million in Q1 2021 to a low of -$568.8 million in Q4 2024.
  • Average Retained Earnings over 5 years is -$312.7 million, with a median of -$321.5 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: crashed 156.47% in 2021, then increased 15.3% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$123.8 million in 2021, then tumbled by 84.59% to -$228.4 million in 2022, then crashed by 66.97% to -$381.4 million in 2023, then plummeted by 49.12% to -$568.8 million in 2024, then grew by 15.3% to -$481.8 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Retained Earnings are -$481.8 million (Q4 2025), -$458.3 million (Q3 2025), and -$451.0 million (Q2 2025).